Cargando…
Management of Diabetes Mellitus in Normal Renal Function, Renal Dysfunction and Renal Transplant Recipients, Focusing on Glucagon-Like Peptide-1 Agonist: A Review Based upon Current Evidence
Diabetes Mellitus (DM) is a leading cause of both Cardiovascular Disease (CVD) and End-stage Renal Disease (ESRD). After 2008, there has been much evidence presented, and recently the guidelines for sugar control have changed to focus on being more disease orientated. GLP-1 Receptor Agonists (GLP-1R...
Autores principales: | Tsai, Shang-Feng, Chen, Cheng-Hsu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651241/ https://www.ncbi.nlm.nih.gov/pubmed/31261624 http://dx.doi.org/10.3390/ijms20133152 |
Ejemplares similares
-
The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease
por: Lin, Yuan, et al.
Publicado: (2023) -
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
por: Yin, Win L., et al.
Publicado: (2020) -
Renal cortical necrosis in a renal transplant recipient
por: Eswarappa, M., et al.
Publicado: (2013) -
Tuberculosis in renal transplant recipients
por: Sundaram, Madhivanan, et al.
Publicado: (2008) -
Tuberculosis in renal transplant recipient
por: Kalita, P., et al.
Publicado: (2010)